TRDA
Entrada Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Strong sell
-62/100
Last price
5.58
▲ 0.16 (2.95%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
5.33
Prev close
5.42
Day high
5.60
Day low
5.32
Volume
81.89K
Market cap
$217.27M
P/E (TTM)
—
52W range
5.15 – 16.45
Day trading desk
Gap from prior close
-1.66%
Prior close 5.42
VWAP
5.51
+1.34% from price
Relative volume
0.22×
Quiet session
Session range
5.14%
5.32 – 5.59
Position in range
95%
Near session high
ATR (14D)
0.39
7.04% of price
Prior day high
5.52
PDH
Prior day low
5.25
PDL
Bid / ask spread
—
Quote not published
Session volume
78.91K
Avg 362.82K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-12.13%
-13.9%
1M
-25.80%
-27.2%
3M
-24.59%
-27.9%
6M
-61.03%
-75.9%
YTD
-45.72%
-59.6%
1Y
-5.74%
-21.3%
3Y
-62.42%
-144.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TRDA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-967.87K
Net selling
Buy transactions
2
20.00K shares
Sell transactions
10
987.87K shares
Net transactions
+12
Buys less sells
Sell : buy shares
49.4 : 1
Heavily one-sided
Insider-held shares
4.41M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 9, 26 | MPM BIOVENTURES 2014,L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 259.84K | $1.91M | Indirect |
| Sep 3, 26 | MPM BIOVENTURES 2014,L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 86.48K | $617.38K | Indirect |
| Aug 31, 26 | MPM BIOVENTURES 2014,L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 86.91K | $615.78K | Indirect |
| Aug 26, 26 | MPM BIOVENTURES 2014,L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 62.71K | $461.55K | Indirect |
| Aug 10, 26 | PARMAR KUSH M Director |
SELL | 155.25K | $1.08M | Indirect |
| Aug 7, 26 | 5AM VENTURES V, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 62.81K | $431.83K | Indirect |
| Jul 31, 26 | PARMAR KUSH M Director and Beneficial Owner of more than 10% of a Class of Security |
SELL | 116.47K | $807.03K | Indirect |
| Jul 31, 26 | 5AM VENTURES V, L.P. Beneficial Owner of more than 10% of a Class of Security |
SELL | 116.47K | $807.03K | Indirect |
| May 20, 26 | ZEIHER BERNHARDT G Director |
BUY | 5.00K | $29.32K | Indirect |
| May 4, 26 | DOWDEN NATHAN J President |
SELL | 15.00K | $229.95K | Direct |
| May 4, 26 | SETHURAMAN NATARAJAN Officer |
SELL | 25.91K | $398.81K | Direct |
| May 4, 26 | DOWDEN NATHAN J President |
CONVERSION | 15.00K | $26.10K | Direct |
| Apr 1, 26 | WENTWORTH KORY JAMES Chief Financial Officer |
SELL | 2.50K | $32.38K | Direct |
| Mar 10, 26 | WENTWORTH KORY JAMES Chief Financial Officer |
SELL | 16.48K | $214.38K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
5AM VENTURES V, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
BAKER BROS ADVISORS L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
DOSHI DIPAL |
Chief Executive Officer | 526.01K | Stock Award(Grant) |
DOWDEN NATHAN J |
President | 198.59K | Sale |
MPM BIOVENTURES 2014,L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
MPM BIOVENTURES III, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
PARMAR KUSH M |
Director | — | Sale |
SETHURAMAN NATARAJAN |
Officer | 216.32K | Sale |
WENTWORTH KORY JAMES |
Chief Financial Officer | 119.01K | Sale |
ZEIHER BERNHARDT G |
Director | — | Purchase |
Fundamentals
Market cap$217.27M
Enterprise value$20.97M
Revenue (TTM)$4.69M
Gross profit$-134.36M
EBITDA$-170.86M
Net income$-165.78M
EPS (TTM)$-3.96
Free cash flow$-77.67M
Total cash$223.00M
Total debt$48.54M
Book value / share$6.47
Shares outstanding38.94M
Float22.67M
Short % of float10.94%
Dividend yield0.00%
Beta (5Y)-0.24
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.85
PEG ratio—
Price / sales—
Price / book0.86
EV / revenue4.48
EV / EBITDA-0.12
Gross margin0.00%
Operating margin-5007.02%
Profit margin0.00%
Return on equity-54.10%
Return on assets-29.20%
Debt / equity20.80
Current ratio10.89
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $25.42M | $210.78M | $129.01M | $0 | -87.9% |
| Operating revenue | $25.42M | $210.78M | $129.01M | $0 | -87.9% |
| Research & development | $142.27M | $125.31M | $99.88M | $66.61M | +13.5% |
| Selling, general & admin | $41.05M | $38.47M | $32.29M | $30.64M | +6.7% |
| Total operating expense | $183.32M | $163.77M | $132.18M | $97.25M | +11.9% |
| Operating income | -$157.90M | $47.01M | -$3.16M | -$97.25M | -435.9% |
| Net interest income | $15.07M | $19.47M | $15.22M | $2.63M | -22.6% |
| Pre-tax income | -$142.83M | $66.48M | $12.06M | -$94.62M | -314.8% |
| Tax provision | $924.00K | $859.00K | $18.74M | $0 | +7.6% |
| Net income | -$143.75M | $65.63M | -$6.68M | -$94.62M | -319.0% |
| Net income to common | -$143.75M | $65.63M | -$6.68M | -$94.62M | -319.0% |
| Basic EPS | -3.47 | 1.76 | -0.20 | -3.02 | -297.2% |
| Diluted EPS | -3.47 | 1.68 | -0.20 | -3.02 | -306.5% |
| EBIT | -$157.90M | $47.01M | -$3.16M | -$97.25M | -435.9% |
| EBITDA | -$153.80M | $50.78M | -$321.00K | -$95.35M | -402.9% |
| Basic shares | 41.37M | 37.31M | 33.05M | 31.29M | +10.9% |
| Diluted shares | 41.37M | 39.00M | 33.05M | 31.29M | +6.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $90.39M | $101.21M | $67.60M | $45.16M | -10.7% |
| Cash & short-term investments | $295.70M | $420.00M | $351.97M | $188.71M | -29.6% |
| Total current assets | $306.25M | $440.04M | $369.77M | $209.88M | -30.4% |
| Property, plant & equipment | $67.76M | $82.05M | $92.68M | $33.02M | -17.4% |
| Total assets | $377.38M | $526.32M | $469.19M | $252.06M | -28.3% |
| Total current liabilities | $24.45M | $39.48M | $158.80M | $21.97M | -38.1% |
| Total debt | $50.93M | $59.21M | $68.23M | $25.94M | -14.0% |
| Total liabilities | $71.25M | $97.64M | $226.83M | $39.50M | -27.0% |
| Retained earnings | -$273.09M | -$129.34M | -$194.97M | -$188.28M | -111.1% |
| Shareholder equity | $306.13M | $428.68M | $242.36M | $212.55M | -28.6% |
| Working capital | $281.80M | $400.56M | $210.97M | $187.90M | -29.6% |
| Net tangible assets | $306.13M | $428.68M | $242.36M | $212.55M | -28.6% |
| Shares issued | 38.28M | 37.57M | 33.44M | 31.39M | +1.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$143.75M | $65.63M | -$6.68M | -$94.62M | -319.0% |
| Depreciation & amortisation | $4.10M | $3.77M | $2.84M | $1.90M | +8.6% |
| Stock-based compensation | $19.61M | $17.91M | $13.11M | $9.89M | +9.5% |
| Change in working capital | -$4.80M | -$118.85M | $136.31M | -$11.11M | +96.0% |
| Operating cash flow | -$128.51M | -$41.56M | $139.80M | -$93.79M | -209.2% |
| Capital expenditure | -$1.04M | -$3.16M | -$5.61M | -$2.89M | +67.0% |
| Investing cash flow | $116.81M | -$27.80M | -$138.40M | -$148.65M | +520.2% |
| Financing cash flow | $887.00K | $102.96M | $21.04M | $479.00K | -99.1% |
| Free cash flow | -$129.55M | -$44.72M | $134.19M | -$96.67M | -189.7% |
| End cash position | $94.34M | $105.16M | $71.55M | $49.11M | -10.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $898.00K | $875.00K | $1.30M | $1.61M | $1.95M | +2.6% |
| Operating revenue | $898.00K | $875.00K | $1.30M | $1.61M | $1.95M | +2.6% |
| Research & development | $35.37M | $33.05M | $33.96M | $38.36M | $37.88M | +7.0% |
| Selling, general & admin | $10.49M | $10.12M | $9.55M | $10.30M | $10.92M | +3.6% |
| Total operating expense | $45.86M | $43.18M | $43.51M | $48.66M | $48.80M | +6.2% |
| Operating income | -$44.96M | -$42.30M | -$42.21M | -$47.05M | -$46.85M | -6.3% |
| Net interest income | $2.23M | $2.62M | $3.14M | $3.57M | $3.92M | -14.8% |
| Pre-tax income | -$42.73M | -$39.68M | -$39.07M | -$43.48M | -$42.92M | -7.7% |
| Tax provision | $35.00K | $38.00K | $92.00K | $654.00K | $178.00K | -7.9% |
| Net income | -$42.76M | -$39.72M | -$39.16M | -$44.13M | -$43.10M | -7.7% |
| Net income to common | -$42.76M | -$39.72M | -$39.16M | -$44.13M | -$43.10M | -7.7% |
| Basic EPS | -1.01 | -0.95 | -0.94 | -1.06 | -1.04 | -6.3% |
| Diluted EPS | -1.01 | -0.95 | -0.94 | -1.06 | -1.04 | -6.3% |
| EBIT | -$44.96M | -$42.30M | -$42.21M | -$47.05M | -$46.85M | -6.3% |
| EBITDA | -$44.12M | -$41.50M | -$41.32M | -$45.82M | -$45.81M | -6.3% |
| Basic shares | 42.22M | 41.84M | 41.60M | 41.46M | 41.34M | +0.9% |
| Diluted shares | 42.22M | 41.84M | 41.60M | 41.46M | 41.34M | +0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $99.28M | $76.44M | $90.39M | $93.29M | $72.48M | — | +29.9% |
| Cash & short-term investments | $223.00M | $76.44M | $295.70M | $326.84M | $354.01M | — | +191.7% |
| Total current assets | $232.70M | $266.87M | $306.25M | $338.26M | $369.15M | — | -12.8% |
| Property, plant & equipment | $62.76M | — | $67.76M | $70.53M | $75.49M | $79.10M | — |
| Total assets | $298.88M | $335.52M | $377.38M | $412.90M | $448.78M | — | -10.9% |
| Total current liabilities | $21.37M | $19.20M | $24.45M | $24.02M | $19.80M | — | +11.3% |
| Total debt | $48.54M | $49.75M | $50.93M | $52.40M | $54.74M | — | -2.4% |
| Total liabilities | $65.47M | $64.66M | $71.25M | $72.18M | $69.28M | — | +1.2% |
| Retained earnings | -$355.57M | -$312.81M | -$273.09M | -$233.93M | -$189.80M | — | -13.7% |
| Shareholder equity | $233.41M | $270.60M | $306.13M | $340.72M | $379.50M | — | -13.7% |
| Working capital | $211.33M | $247.68M | $281.80M | $314.24M | $349.34M | — | -14.7% |
| Net tangible assets | $233.41M | $270.60M | $306.13M | $340.72M | $379.50M | — | -13.7% |
| Shares issued | 38.94M | 38.82M | 38.28M | 38.22M | 38.03M | — | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$42.76M | -$39.72M | -$39.16M | -$44.13M | -$43.10M | — | -7.7% |
| Depreciation & amortisation | $841.00K | $805.00K | $886.00K | $1.23M | $1.03M | — | +4.5% |
| Stock-based compensation | $5.15M | $4.74M | $4.36M | $5.12M | $5.05M | — | +8.6% |
| Change in working capital | $4.76M | -$6.98M | $2.35M | $10.21M | $8.49M | — | +168.2% |
| Operating cash flow | -$32.46M | -$41.70M | -$32.20M | -$28.31M | -$29.49M | — | +22.1% |
| Capital expenditure | -$11.00K | -$44.00K | — | — | -$275.00K | -$1.14M | +75.0% |
| Investing cash flow | $54.95M | $26.99M | $29.12M | $49.11M | $33.80M | — | +103.6% |
| Financing cash flow | $350.00K | $100.00K | $192.00K | $8.00K | $337.00K | — | +250.0% |
| Free cash flow | -$32.47M | -$41.74M | -$32.00M | -$28.14M | -$29.76M | — | +22.2% |
| End cash position | $102.57M | $79.74M | $94.34M | $97.24M | $76.43M | — | +28.6% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
2.50
-55.2% from spot
ATM implied vol
644.5%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
12
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
5.00
8 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.04 | -1.01 | +3.2% |
| Mar 2026 | -1.02 | -0.95 | +6.9% |
| Dec 2025 | -1.16 | -0.94 | +18.7% |
| Sep 2025 | -0.97 | -1.06 | -9.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.99 | 7 | $5.26M | +225.8% |
| Next quarter | -0.88 | 7 | $9.83M | +656.6% |
| Current year | -3.79 | 7 | $12.17M | -52.1% |
| Next year | -3.01 | 6 | $22.86M | +87.9% |
Analyst targets & ownership
Mean target$19.00
High target$25.00
Low target$11.00
Implied upside240.50%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 7
Hold1
Sell / Strong sell0 / 0
Held by insiders12.23%
Held by institutions82.11%
Institutions holding181
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
5.87
-5.02% from price
SMA 20
6.31
-11.63% from price
SMA 50
6.85
-18.51% from price
SMA 100
6.79
-17.83% from price
SMA 200
9.24
-39.64% from price
EMA 12
5.94
-6.00% from price
EMA 26
6.34
-11.93% from price
EMA 50
6.69
-16.58% from price
RSI (14)
34.5
Neutral
MACD (12,26,9)
-0.40
Hist -0.10
ATR (14)
0.39
7.04% of price
Realised vol 30D
65.3%
Annualised
Bollinger upper
7.38
20, 2σ
Bollinger lower
5.25
20, 2σ
50 / 200 cross
Death
6.85 vs 9.24
Trend bias
Below 200
-39.64%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.41
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
65.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-66.4%
Peak to trough
Max drawdown 5Y
-85.7%
Peak to trough
ATR 14
0.39
7.04% of price
Beta (reported)
-0.24
5Y monthly, from filing
Short interest
Shares short
2.74M
Prior 2.37M
Change vs prior
+15.9%
Shorts adding
% of float
10.94%
Elevated
% of shares out
7.05%
Against total outstanding
Days to cover
9.7
Crowded exit
Float
22.67M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 8, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| May 8, 26 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Apr 6, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Feb 18, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 11, 26 | Guggenheim | INITIATED | — | Buy |
| May 20, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 31, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 25, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 4, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 5, 24 | Roth MKM | INITIATED | — | Buy |
| Nov 6, 24 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Nov 6, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-05-19
Periodic Financial Reports
10-Q · 2026-05-07
Proxy Statements
DEFA14A · 2026-04-29
Proxy Statements
DEFA14A · 2026-04-24
Offering Registrations
S-8 · 2026-02-26
Corporate Changes & Voting Matters
8-K · 2026-01-08
Headlines
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
GlobeNewswire · 27d ago
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 35d ago
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 63d ago
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
GlobeNewswire · 63d ago
Entrada Therapeutics Insider Sold Shares Worth $807,027, According to a Recent SEC Filing
MT Newswires · 65d ago
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 69d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.